Post-transplant lymphoproliferative disease in children

Area of Science:

• Pediatric Oncology
• Transplantation Immunology
• Virology

Background:

• Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD) significantly impacts pediatric transplant recipients.
• PTLD incidence and outcomes differ between children and adults, with higher frequency in younger patients.

Purpose of the Study:

• To analyze the incidence, outcomes, and diagnostic markers of EBV-driven PTLD in pediatric organ transplant recipients.
• To investigate the correlation between the timing of PTLD onset, EBV serology, and patient survival.

Main Methods:

• Retrospective analysis of 22 pediatric organ transplant recipients diagnosed with PTLD between 1989 and 1998.
• Evaluation of PTLD onset timing (early vs. late post-transplant), EBV serologic status at diagnosis, and survival rates.
• In situ hybridization for EBER1 mRNA to detect EBV in tissue samples.

Main Results:

• PTLD developed in 5% of pediatric transplant recipients, with a mortality rate of 50% (11 of 22).
• Patients developing PTLD <6 months post-transplant had a 100% mortality rate, versus 31% for those diagnosed >6 months post-transplant (p=0.0002).
• Serologic evidence of EBV infection at diagnosis was associated with better survival (91% vs. 25%, p=0.04), and EBER1 mRNA detection was highly sensitive for B-cell PTLD.

Conclusions:

• The timing of PTLD onset post-transplant is a critical prognostic factor in pediatric patients.
• EBV seroconversion can indicate risk but also reflect sufficient immune function for survival.
• In situ hybridization for EBER1 mRNA is a valuable diagnostic tool for EBV-related PTLD.